(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 12.87% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Dexcom's revenue in 2026 is $4,662,000,000.On average, 33 Wall Street analysts forecast DXCM's revenue for 2026 to be $2,054,023,661,754, with the lowest DXCM revenue forecast at $1,952,804,208,308, and the highest DXCM revenue forecast at $2,164,864,736,250. On average, 33 Wall Street analysts forecast DXCM's revenue for 2027 to be $2,308,419,322,316, with the lowest DXCM revenue forecast at $2,167,173,925,302, and the highest DXCM revenue forecast at $2,467,753,366,904.
In 2028, DXCM is forecast to generate $2,585,137,143,714 in revenue, with the lowest revenue forecast at $2,359,991,211,144 and the highest revenue forecast at $2,788,730,645,132.